Back to mobile site

OptimizeRX (OPRX) Reiterated at Market Outperform by Citizens Amid Upsell Opportunity

June 29, 2026 4:44 AM EDT Send to a Friend
Citizens analyst Constantine Davides reiterated a Market Outperform rating and $9.00 price target on OptimizeRX (NASDAQ: OPRX).The analyst commented, "Management ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login